Zhao Pengfei, Qi Ying
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Front Pharmacol. 2024 Jun 21;15:1429971. doi: 10.3389/fphar.2024.1429971. eCollection 2024.
Ampiroxicam is a long-acting, non-steroidal anti-inflammatory drug that selectively inhibits human cyclooxygenase, effectively mitigating fever, pain, and inflammation. This study evaluated the drug's tolerability and pharmacokinetics to support personalized dosing strategies. The study involved healthy participants and focused on the pharmacokinetics of ampiroxicam. Plasma levels of piroxicam, a key metabolite of ampiroxicam, were measured using ultra-performance liquid chromatography. Piroxicam was chosen due to its integral role in ampiroxicam's metabolic pathway. The analytical method underwent rigorous validation to ensure precision and accuracy, addressing potential interference from endogenous plasma substances. Participants received ampiroxicam in single doses (low, medium, and high) and multiple doses. Pharmacokinetic parameters, including AUC, AUC, and C, exhibited a dose-dependent increase. No significant differences were noted across the dosage groups, and sex-specific differences were minimal, with the exception of mean residence time (MRT) in the multiple-dose group, which appeared influenced by body weight variations. The findings affirm the safety and efficacy of ampiroxicam across different dosing regimens, validating its clinical utility and potential for personalized medicine in the treatment of pain and inflammation.
安吡昔康是一种长效非甾体抗炎药，可选择性抑制人体环氧化酶，有效减轻发热、疼痛和炎症。本研究评估了该药物的耐受性和药代动力学，以支持个性化给药策略。该研究纳入了健康参与者，重点关注安吡昔康的药代动力学。使用超高效液相色谱法测量了安吡昔康的关键代谢产物吡罗昔康的血浆水平。选择吡罗昔康是因为其在安吡昔康代谢途径中的重要作用。该分析方法经过了严格验证，以确保准确性和精密度，解决内源性血浆物质的潜在干扰。参与者接受了单剂量（低、中、高）和多剂量的安吡昔康。药代动力学参数，包括AUC、AUC和C，呈现出剂量依赖性增加。各剂量组之间未观察到显著差异，性别差异最小，但多剂量组的平均驻留时间（MRT）似乎受体重变化影响。研究结果证实了安吡昔康在不同给药方案下的安全性和有效性，验证了其在疼痛和炎症治疗中的临床实用性和个性化医疗潜力。
